Genetics is slowly explaining variations in drug response, but applying this knowledge depends on implementation of a host of policies that provide long-term support to the field, from translational research and regulation to professional education.
The linking of genetic factors to drug response that is at the core of pharmacogenetics has for some time been regarded as a key hope for the drug industry. The structure of the industry, and especially its bases in dedicated SMEs, noncommercial labs and government regulation, is assessed here. The paper argues that it is factors in the demand side that are mostly restricting the segment¿s growth. Dr Hopkins led this study and drafted the paper 80% himself, drawing on data collected and/or prepared by all other authors.